Welcome to the Definitive Industry Forum for Chronic HBV Drug Development

While direct acting antiviral therapies have been effective in controlling viral replication, it’s clear that combination therapy with multiple mechanisms of action may be the key to achieving functional cure in chronic HBV, and the landscape for drug development in antiviral agents and immune modulation has never been more exciting.

Uniting 20+ industry heavyweights, the 2nd Chronic HBV Drug Development Summit is the definitive industry forum focusing exclusively on late translational through to phase II clinical trials for chronic HBV.

Hear from Gilead Sciences, Vir Biotechnology, VBI Vaccines, Drug Farm, Replicor, GSK, Assembly Biosciences and many more accelerating the frontier of novel therapies beyond the current standard of care to move the needle on functional cure.

From dissecting pivotal insight into sequencing multiple mechanisms of action acting on immune and viral targets to attain durable treatment, to leveraging advances in prediction of efficacy with novel serum markers including HBV RNA and core-related antigen, the HBV Summit is dedicated to driving progress in combination therapy paradigms.

Delineate clinically meaningful hepatitis B surface antigen loss to establish a pathway to finite treatment, explore the latest updates on immunotherapies in development to illuminate opportunities to restore antiviral immunity,

Join us in Boston to forge successful industry collaborations in combination therapy for chronic HBV.

Expert Speakers Include:

Andrew Vaillant

Chief Scientific Officer


Herbert Virgin

Chief Scientific Officer & Executive Vice President of Research

Vir Biotechnology

Luisa Stamm

Chief Medical Officer

Assembly Biosciences

Patricia Mendez

Head HBV Cure

Gilead Sciences

David Anderson

Chief Scientific Officer

VBI Vaccines

Jeysen Yogaratnam

Chief Medical Officer

Drug Farm

Shihyun You

Senior Scientific Director


Timothy Block


Hepatitis B Foundation